<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621447</url>
  </required_header>
  <id_info>
    <org_study_id>10060080</org_study_id>
    <nct_id>NCT05621447</nct_id>
  </id_info>
  <brief_title>A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects</brief_title>
  <official_title>A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite&#xD;
      identification of [14C]TAS-303 following oral single dose&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Actual">November 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of total radioactivity in blood and plasma</measure>
    <time_frame>Day1 to 8 and 10,12,14,16,18,20,22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma TAS-303 concentrations</measure>
    <time_frame>Day1 to 8 and 10,12,14,16,18,20,22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day1 to 8 and 10,12,14,16,18,20,22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC).</measure>
    <time_frame>Day1 to 8 and 10,12,14,16,18,20,22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half life (T1/2)</measure>
    <time_frame>Day1 to 8 and 10,12,14,16,18,20,22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity cumulative excretion rate into urine</measure>
    <time_frame>Day 1 to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity cumulative excretion rate into feces.</measure>
    <time_frame>Day 1 to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity excretion and excretion rate，cumulative excretion, cumulative excretion rate in all excreta (urine and feces).</measure>
    <time_frame>Day 1 to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>The number and incidence of Adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>The number and incidence of Treatment-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>Screening period and Day -2, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Screening period and Day 1, 2, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>Screening period and Day 1, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Screening period and Day 1, 2, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>Screening period and Day 1, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Screening period and Day 1, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>TAS-303, [14C]TAS-303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-303, [14C]TAS-303</intervention_name>
    <description>oral administration on day 1</description>
    <arm_group_label>TAS-303, [14C]TAS-303</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male subjects who provided written informed consent to participate in&#xD;
             the study&#xD;
&#xD;
          2. Aged 18 years or older and younger than 40 years at the time of informed consent&#xD;
&#xD;
          3. Capable of oral intake.&#xD;
&#xD;
          4. Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0&#xD;
&#xD;
          5. Had blood pressure, pulse rate, and body temperature meeting any of the following at&#xD;
             screening:&#xD;
&#xD;
        Systolic blood pressure: ≧90 mmHg and ≦139 mmHg, Diastolic blood pressure: ≧40 mmHg and ≦89&#xD;
        mmHg, Pulse rate: ≧40 beats per minute (bpm) and ≦99 bpm, Body temperature: ≧35.0°C and&#xD;
        ≦37.4°C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had current or previous hypersensitivity or allergy to drugs&#xD;
&#xD;
          2. Had current or previous drug abuse (including use of illicit drugs) or alcoholism&#xD;
&#xD;
          3. Had any concurrent disease (including symptoms and signs; however, diseases that do&#xD;
             not affect evaluations in the study such as asymptomatic pollinosis and wart are&#xD;
             excluded)&#xD;
&#xD;
          4. Received a radioisotope-labeled substance or subject to a large quantity of radiation&#xD;
             exposure* within 12 months before the first dose of TAS-303.&#xD;
&#xD;
             * A large quantity of radiation exposure includes continuous X-ray irradiation,&#xD;
             computed tomography (CT) scan, gastric barium test, and positron emission tomography&#xD;
             (PET) scan, excluding tests with low radiation exposure (e.g., chest, bone, or dental&#xD;
             X-ray examination, or X-ray examination before boarding an airplane).&#xD;
&#xD;
          5. Occupationally exposed to radiation within a year before the first dose of TAS-303&#xD;
             (such as operators who are involved in nuclear power or radiation operations).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A site selected by Taiho Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 30, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>February 3, 2023</last_update_submitted>
  <last_update_submitted_qc>February 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared according to the Sponsor policy on data sharing. Taiho policy on data sharing may be found at https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

